|
PASG | Passage Bio, Inc. |
|
|
PASG | Passage Bio, Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.09 |
| Leverage | 51.69% |
| Market Cap | $ 404.2m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -56.7m |
| Margin | -1159.07% |
Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company is headquartered in Philadelphia, Pennsylvania.